ST13

Overview

ST13, an ortho-hydroxyanilide, is a selective, slow- and tight-binding HDAC1 and HDAC2 inhibitor with IC 50 s of 23 nM and 49 nM, respectively. ST13 shows a weak inhibition of HDAC3 (IC 50 = 4.30 μM) and HDAC6 (IC 50 > 10 μM). The induced fit mechanism of ST13 proceeds through a two-step process: first, the enzyme and inhibitor rapidly form a collision complex (EI), which then slowly transforms into the stable complex E*I. ST13 induces apoptosis in cancer cells. ST13 can be used for the study of melanoma and triple-negative breast.

Application

Products | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Melanoma | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > HDAC | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-179654
• CAS No.: 1013620-98-8
• Molecular Formula: C21H18N2O3
• Molecular Weight: 346.38
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source